Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Информационное письмо о регистрации нового перорального контрацептива Джес в России
Информационное письмо о регистрации нового перорального контрацептива Джес в России
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Sitruk-Ware R. New progestagens for contraceptive use. Human Reproduction Update 2006; 12 (2): 169–78.
2. Mishell DR, Jr. Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations. Contraception 2005; 71: 304–5.
3. Klipping C, Duijkers I, Trummer D et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008.
4. Gruber C, Marr J, Anttila L. A randomized study comparing the bleeding pattern of a 24-day regimen of ethinylestradiol 20mcg plus drospirenone 3mg COC with a 21-day regimen of ethinylestradiol 20mcg plus desogestrel 150mcg COC. XVIII World Congress of Gynaecology & Obstetrics (FIGO) Kuala Lumpur, Malaysia, 5–10 November 2006.
5. Bachmann G, Sulak PJ, Sampson-Landers C et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containin 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 2004; 70: 191–8.
6. Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106 (3): 492–501.
7. Koltun W, Lucky A, Sampson-Landers C et al. A randomized controlled trial of a low-dose COC containing ethinylestradiol 20 mcg + drospirenone 3mg in the treatment of acne vulgaris: i) reduction in acne lesions, and investigator global assessment. XVIII World Congress of Gynaecology & Obstetrics (FIGO) Kuala Lumpur, Malaysia, 5–10 November 2006.
2. Mishell DR, Jr. Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations. Contraception 2005; 71: 304–5.
3. Klipping C, Duijkers I, Trummer D et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008.
4. Gruber C, Marr J, Anttila L. A randomized study comparing the bleeding pattern of a 24-day regimen of ethinylestradiol 20mcg plus drospirenone 3mg COC with a 21-day regimen of ethinylestradiol 20mcg plus desogestrel 150mcg COC. XVIII World Congress of Gynaecology & Obstetrics (FIGO) Kuala Lumpur, Malaysia, 5–10 November 2006.
5. Bachmann G, Sulak PJ, Sampson-Landers C et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containin 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 2004; 70: 191–8.
6. Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106 (3): 492–501.
7. Koltun W, Lucky A, Sampson-Landers C et al. A randomized controlled trial of a low-dose COC containing ethinylestradiol 20 mcg + drospirenone 3mg in the treatment of acne vulgaris: i) reduction in acne lesions, and investigator global assessment. XVIII World Congress of Gynaecology & Obstetrics (FIGO) Kuala Lumpur, Malaysia, 5–10 November 2006.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.